Delivery of chemo-sensitizing siRNAs to HER2(+)-breast cancer cells using RNA aptamers

Human epidermal growth factor receptor 2 (HER2) expression in breast cancer is associated with an aggressive phenotype and poor prognosis, making it an appealing therapeutic target. Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Thiel, Kristina W., Hernandez, Luiza I., Dassie, Justin P., Thiel, William H., Liu, Xiuying, Stockdale, Katie R., Rothman, Alissa M., Hernandez, Frank J., McNamara, James O., Giangrande, Paloma H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
RNA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401474/
https://www.ncbi.nlm.nih.gov/pubmed/22467215
http://dx.doi.org/10.1093/nar/gks294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401474/
https://www.ncbi.nlm.nih.gov/pubmed/22467215
http://dx.doi.org/10.1093/nar/gks294

Ejemplares similares